Список литературы

Поставить закладку

Имянитов Е.Н. Молекулярные механизмы опухолевого роста // Вопросы онкологии. – 2010. – Т.56, № 2. – С. 117-128.
. Клинически значимые морфологические параметры почечно-клеточного рака / Москвина Л.В., Андреева Ю.Ю., Мальков П.Г. [с соавт.] // Онкология – 2013. – №4. – C.34-39.
Корман Д.Б. Основы противоопухолевой химиотерапии // Практическая Медицина – 2006. – С.503.
Молекулярные маркеры рака мочевого пузыря: от частного к целому / Заболотнева А.А., Гайфуллин Н.М., Буздин А.А. [с соавт.] // Онкоурология. – 2011. – Т.3. – С. 16-19.
Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность) // М.: «МНИОИ им. П.А. Герцена» Минздрава РФ, 2012. – 260с.
Ярилин А.А. Иммунология. – М.: ГЭОТАР Медиа, 2010. – 749 c.
Bukowski R.M. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma // Expert. Opin. Investig. Drug – 2003. – Vol.12. – P.1403-1411.
Cohen H.T., McGovern F.J. Renal-cell carcinoma. // N. Engl. Med. – 2005. – Vol.353, №2. – 2477-2490.
.Comparisonof virtual cystoscopy and ultrasonography forbladder cancer detection: A meta-analysis / Qu X., Huang X., Wu L. [et al.] // Eur. J. Radiol. 2010. – Vol. 93– P.432-439.
Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney / Ernest S., Rajaraman S., Megyesi J. [et al.] // Nephron. – 1997. – Vol. 77. – P.284-289.
Global cancer statistics, 2002 CA / Parkin D.M., Bray F., Ferlay J. [et al.] // Cancer J. Clin. – 2005. – Vol.55, №2. – P.74–108.
Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality? // Nat. Med. – 2009. – Vol. 61. – P.759-767.
Hanahan D., Weinderg R.A. The hallmarks of cancer. Cell. – 2000. – Vol.100. – P.57-70.
Huland E., Heinzer H. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen // Br. J. Cancer. – 2000. – Vol.82. – P.246-247.
IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma:long-term results of a controlled randomized clinical trial / Atzpodien J., Kirchner H., Illiger H.J. [et al.] // Br. J. Cancer – 2001. – Vol.85. – P. 130-136.
Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma / Motzer R.J., Bacik J., Murphy B.A. [et al.] // J. Clin. Oncol. – 2002. – Vol.20. – P.89-96.
Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene / Fojo A.T., Shen D.W., Mickley L.A. [et al.] // J. Clin.Oncol. – 1987. – Vol.5. – P.1922-1927.
Kaufman D.S., Shipley W.U., Feldman A.S. // Bladder cancer. – Lancet. – 2009. – Vol.374, №9685. – P.239-249.
Knowles M.A. Molecular pathogenesis of bladder cancer // Int. J. Clin. Oncol. – 2008. – Vol.13, №4. – Р.287-297.
Microsatellite analysis–DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial / Van Rhijn B.W., Lurkin I., Kirkels W.J. [et al.] // Cancer – 2001. – Vol.92, №4. – Р.768-775.
Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma // J. Urol. – 2000. – Vol.163. – P.408-417.
O' Donoghue P.M., McSweeney S.E., Jhaveri K. Genitourinary imaging: current and emergingapplications // J. Postgrad. Med. – 2010. – Vol.56, №2. – Р.131-139.
Oliver R.T.D., Mehta A., Barnett M.J. A phase 2 study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression // Mol. Biother. – 1998. – Vol.1. – P.14-20.
Ploeg M., Aben K.K., Kiemeney L.A.The present and future burden of urinary bladder cancer in the world // World J. Urol, – 2009. – Vol. 27, №3. – P.289-293.
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma / Motzer R.J., Bacik J., Schwartz L.H. [et al.] // J. Clin. Oncol. – 2004. – Vol.22, №3. – P.454-463.
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience / Patard J.J., Leray E., Rioux-Leclercq N., Cindolo L. [et. al.] // J. Clin. Oncоl. – 2005. – Vol.23, №12. – Р.2763-2771.
Riley L.B., Desai D.C. The molecular basis of cancer and the development of targeted therapy // Surg. Clin. North. Amer. – 2009. – Vol.89. – P.1-15.
Surveilance after radical orpartial nephrectomy for localized renal cellcarcinoma and management of recurrent disease / Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. // Urol. Clin. North. Amer. – 2003. – Vol.30, №4. – P.843-852.
Systemic endocrine instigation of indolent tumor growth requires osteopontin McAllister S.S., Gifford A.M., Greiner A.L. [et al.] // Cell – 2008. – Vol. 133. –P. 994-1005.
The effects of surgery on tumor growth: a century of investigations / Demicheli R., Retsky M.W., Hrushesky W.J. [et al.] // Ann. Oncol. – 2008. – Vol.19. – P.1821-1828.
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis / Maxwell P.H., Wiesener M.S., Chang G.W. [et al.] // Nature. – 1999. – Vol.99. – P.271-275.
Vogelzang N.J., Priest E.R., Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up // J. Urol. – 1992. – Vol.148. – P.1247-1248.
Weinderg R.A Mechanisms of malignant progression // Carcinogenesis – 2008. – Vol.29. – P.1092-1105.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница